These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23816503)

  • 1. Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept.
    Michel M; Henri P; Vincent FB; Leon N; Marcelli C
    Joint Bone Spine; 2013 Dec; 80(6):660-3. PubMed ID: 23816503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of abatacept in rheumatoid arthritis.
    von Kempis J; Dudler J; Hasler P; Kyburz D; Tyndall A; Zufferey P; Villiger PM
    Swiss Med Wkly; 2012; 142():w13581. PubMed ID: 22581564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of mesangial immunoglobulin IgA glomerulonephritis and p-ANCA positivity in a patient with psoriatic arthritis].
    Nazzaro P; Battaglia R; D'Altri C; Marangi AL; Perniola M; Rodio A; De Padova F
    G Ital Nefrol; 2016; 33(2):. PubMed ID: 27067220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis.
    Kaneko K; Nanki T; Hosoya T; Mizoguchi F; Miyasaka N
    Mod Rheumatol; 2010 Dec; 20(6):632-6. PubMed ID: 20617355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis.
    Korpela M; Mustonen J; Teppo AM; Helin H; Pasternack A
    Br J Rheumatol; 1997 Nov; 36(11):1189-95. PubMed ID: 9402863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of CTLA4-Ig on radiographic outcome of patients with rheumatoid arthritis].
    Harigai M
    Clin Calcium; 2007 Apr; 17(4):577-84. PubMed ID: 17404488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A; Pham DQ
    Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CTLA4-Ig (abatacept)].
    Harigai M
    Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of abatacept in patients with rheumatoid arthritis.
    Atzeni F; Sarzi-Puttini P; Mutti A; Bugatti S; Cavagna L; Caporali R
    Autoimmun Rev; 2013 Oct; 12(12):1115-7. PubMed ID: 23800448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Selective co-stimulation blockade. CTLA4-Ig (Abatacept)].
    Alten R; Märker-Hermann E
    Z Rheumatol; 2010 Sep; 69(7):601-7. PubMed ID: 20703487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.
    Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Li T; Ge Z; Becker JC; Westhovens R
    Ann Intern Med; 2006 Jun; 144(12):865-76. PubMed ID: 16785475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Abatacept on T-Lymphocyte Sub-populations and Immunoglobulins in Patients Affected by Rheumatoid Arthritis.
    Conigliaro P; Triggianese P; Giampà E; Chimenti MS; Kroegler B; Perricone R
    Isr Med Assoc J; 2017 Jul; 19(7):406-410. PubMed ID: 28786253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.
    Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R
    Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.
    Stokes MB; Foster K; Markowitz GS; Ebrahimi F; Hines W; Kaufman D; Moore B; Wolde D; D'Agati VD
    Nephrol Dial Transplant; 2005 Jul; 20(7):1400-6. PubMed ID: 15840673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abatacept for the treatment of rheumatoid arthritis.
    Pombo-Suarez M; Gomez-Reino JJ
    Expert Rev Clin Immunol; 2019 Apr; 15(4):319-326. PubMed ID: 30730220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis.
    Doulton TW; Tucker B; Reardon J; Velasco N
    Clin Nephrol; 2004 Sep; 62(3):234-8. PubMed ID: 15481857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abatacept in the treatment of rheumatoid arthritis.
    Todd DJ; Costenbader KH; Weinblatt ME
    Int J Clin Pract; 2007 Mar; 61(3):494-500. PubMed ID: 17313619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.
    Sibilia J; Westhovens R
    Clin Exp Rheumatol; 2007; 25(5 Suppl 46):S46-56. PubMed ID: 17977488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.